Regor Therapeutics' oral obesity drug RGT-075 shows 5% weight loss at 12 weeks in Phase 2a, trailing incretin pills from ...

Bayer's experimental Parkinson’s disease therapy made from stem cells will soon enter late-stage studies, marking a key test ...

Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held ...

Radiopharmaceutical maker Lantheus Holdings plans to acquire Life Molecular Imaging for $350 million in a bid to build up its ...

Tune Therapeutics raises $175M Series B for epigenetic editing, with hepatitis B drug Tune-401 in the clinic. NEA, Yosemite, ...

Nature journal publishes article suggesting embryo gene editing could prevent major diseases, sparking debate. Study by Peter ...

NeurIPS, the biggest AI research conference, turned Vancouver’s convention center into a battleground for wooing AI talent.

Endpoints Weekly reports on iECURE's gene therapy success for OTC deficiency, FDA CDER director Patrizia Cavazzoni's departure, and Verdiva Bio's $411M launch with Sciwind assets.

Biogen has made an offer to acquire its partner Sage Therapeutics, according to a Friday evening regulatory disclosure, ...

Metsera files for IPO, developing GLP-1 drug MET-097i and other obesity treatments to compete with Eli Lilly and Novo Nordisk ...